Kairos Pharma, LTD. financial data

Symbol
KAPA on NYSE
Location
Los Angeles, CA
Fiscal year end
31 December
Latest financial report
10-Q - Q3 2025 - 14 Nov 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 755% %
Return On Equity -79% %
Return On Assets -71% %

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 20,821,353 shares 62%
Common Stock, Shares, Outstanding 20,821,353 shares 62%
Common Stock, Value, Issued $21,000 USD 62%
Weighted Average Number of Shares Outstanding, Basic 20,206,033 shares 85%
Weighted Average Number of Shares Outstanding, Diluted 20,206,033 shares 85%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense $1,769,000 USD 4243%
General and Administrative Expense $3,839,000 USD 124%
Operating Income (Loss) $5,608,000 USD -275%
Nonoperating Income (Expense) $546,000 USD
Net Income (Loss) Attributable to Parent $5,062,000 USD -34%
Earnings Per Share, Basic 0 USD/shares 30%
Earnings Per Share, Diluted 0 USD/shares 30%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $5,575,000 USD
Assets, Current $6,656,000 USD 40%
Intangible Assets, Net (Excluding Goodwill) $102,000 USD -61%
Assets $8,066,000 USD 61%
Liabilities, Current $402,000 USD -76%
Liabilities $992,000 USD -67%
Retained Earnings (Accumulated Deficit) $12,897,000 USD -65%
Stockholders' Equity Attributable to Parent $7,664,000 USD 130%
Liabilities and Equity $8,066,000 USD 61%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $714,000 USD -2083%
Net Cash Provided by (Used in) Financing Activities $3,058,000 USD
Common Stock, Shares Authorized 100,000,000 shares 0%
Common Stock, Shares, Issued 20,821,353 shares 62%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect $2,344,000 USD
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $5,575,000 USD 73%
Deferred Tax Assets, Valuation Allowance $841,000 USD -47%
Deferred Tax Assets, Gross $448,000 USD
Deferred Tax Assets, Operating Loss Carryforwards $1,199,000 USD 40%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 20,000,000 shares 0%
Unrecognized Tax Benefits $0 USD
Additional Paid in Capital $20,540,000 USD 84%
Preferred Stock, Shares Outstanding 0 shares
Amortization of Intangible Assets $40,000 USD 0%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%